IL5 and Increased total eosinophil count: Because of its restriction to the eosinophil/basophil lineage in humans, IL-5 therapy may attenuate key characteristics of allergic airway inflammation, such as airway eosinophilia, airway remodeling, and AHR, without affecting the function of other immune cells (Trifilieff et al., 2001; Flood-Page et al., 2003; Humbles et al., 2004).